Cell Line News and Research

RSS

Scientists identify previously unknown mechanism that drives tumor spread

Any given tumor is composed of a multitude of cell types that can each look or behave differently from its neighbors.

19 Nov 2020

Cannabidiol oils are equally or less effective at inhibiting certain cancer cell lines

Cannabidiol (CBD) oils are equally or less effective at inhibiting the growth of certain cancer cells compared to pure CBD, according to Penn State College of Medicine researchers.

18 Nov 2020

Natural products and herbal medicines show promise in fight against COVID-19

Researchers in China and the United States have called for more research into the potential prophylactic effects of natural products and herbal medicines on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent coronavirus disease 2019 (COVID-19).

17 Nov 2020

Antifungal agent Itraconazole inhibits SARS CoV-2 in vitro

Itraconazole is a broad-spectrum antifungal agent that has been shown to have some in vitro activity against SARS-CoV-2 by a team of Belgian and German researchers.

16 Nov 2020

Affinity-Bead Assisted Mass Spectrometry for Proteomics

In this interview, Ghaith Hamza from AstraZeneca talks to News-Medical Life Sciences about the basic principles of Affinity-Bead Assisted Mass Spectrometry (Affi-BAMS) and how Affi-BAMS can help target specific proteins for proteomic applications.

From Bruker Daltonics 16 Nov 2020

"Cat's claw" extract inhibits replication of SARS-CoV-2 in vitro

Researchers in Columbia and Peru have shown that Uncaria tomentosa – a woody vine native to South America known of as "Cat's claw" – exerts in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

12 Nov 2020

Researchers discover a mechanism that cells use to degrade microRNAs

UT Southwestern researchers have discovered a mechanism that cells use to degrade microRNAs (miRNAs), genetic molecules that regulate the amounts of proteins in cells.

12 Nov 2020

Human coronaviruses cause processing body loss

Researchers continue to expand their knowledge of coronaviruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen. Now, a new study published on the preprint server bioRxiv in November 2020 describes a vital mechanism whereby the novel SARS-CoV-2 pathogen can restrict the human host response. In doing so, the study explores how this novel feature of SARS-CoV-2 works and how it results in a reshaping of the human host's immune response.

11 Nov 2020

New resource can help predict drug sensitivity and optimize therapeutic strategies

Through large-scale profiling of protein changes in response to drug treatments in cancer cell lines, researchers at The University of Texas MD Anderson Cancer Center have generated a valuable resource to aid in predicting drug sensitivity, to understand therapeutic resistance mechanisms and to identify optimal combination treatment strategies.

6 Nov 2020

Study shows brilacidin strongly inhibits SARS-CoV-2 in laboratory cell lines

A recent study by US researchers reveals that brilacidin, a small synthetic molecule with peptide-like properties, exerts potent in vitro antiviral activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – both as a standalone treatment and in combination with FDA-approved remdesivir. The study is currently available on the bioRxiv preprint server.

4 Nov 2020

Ethacridine blocks SARS-CoV-2 with a distinct mode of action

Now, researchers from the University of California, San Francisco, and Stanford University, California, USA, reported a safe and potent antiseptic for use in humans named ethacridine, which effectively inhibits SARS-CoV-2 even at very low concentrations of EC50 ~ 0.08 µM. Their work has is published on the preprint server bioRxiv*.

1 Nov 2020

Study reveals molecular mechanism that increases the invasiveness of radioresistant cancer cells

Scientists have revealed the molecular mechanism regulating the trafficking of lysosomes that increases the invasiveness of radioresistant cancer cells following radiotherapy.

30 Oct 2020

Seroprevalence and immune response to SARS-CoV-2 in Paris

François Anna et al. published this study in a recent medRxiv* preprint paper, where they present the results of assessing the serological response in the selected population. They tested for specific IgG response against the SARS CoV-2 Nucleoprotein and Spike protein and performed a pseudo-neutralization assay in sera of urban dwellers in Paris.

30 Oct 2020

Antiviral inhibitor DDX42 shows broad activity against Chikungunya, HIV and SARS-CoV-2

By exploiting type 1 interferon's ability to foster an antagonistic cellular environment for viral replication, a research group from France pinpointed DEAD-box RNA helicase DDX42 as an intrinsic inhibitor of HIV, but also other pathogenic viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Chikungunya virus.

29 Oct 2020

Research on autophagy and coronavirus, implicates ULK1

Researchers from the University of British Columbia have discovered that the betacoronavirus-encoded papain-like protease disrupts autophagy, partly by targeting ULK1. Their work is reported on the preprint server bioRxiv* in October 2020.

27 Oct 2020

Transcriptomics identifies possible COVID-19 therapies

By using a diverse set of transcriptomic SARS-CoV-2 signatures, US researchers put to use their previously developed drug repositioning pipeline to pinpoint potential drug candidates for the treatment of coronavirus disease (COVID-19). The study is currently available on bioRxiv preprint server.

26 Oct 2020

Researchers create AI system that matches tumors to best drug combinations

Only 4 percent of all cancer therapeutic drugs under development earn final approval by the U.S. Food and Drug Administration (FDA).

23 Oct 2020

Monoclonal Antibodies: Discovery, Characterization and Challenges

In this interview, News-Medical talks to David Apiyo, a senior manager of applications at Sartorius AG, about monoclonal antibody development and characterization.

22 Oct 2020

ACE2 binding causes dissociation of trimeric SARS-CoV-2 spike, may be used to inhibit further infection

A recent study published on the preprint server bioRxiv in October 2020 shows that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binding to the human host receptor could cause the typical trimeric spike protein to come apart, forming a stable monomer instead with the receptor.

14 Oct 2020

Zinc deficiency linked to poor COVID-19 outcomes

A team of researchers from various universities and institutes in Spain recently published a paper on the preprint server medRxiv,* in which they hypothesize that serum zinc levels have a significant influence on COVID-19 progression and thus may be a useful biomarker in predicting severe disease in early stages of COVID-19 infection.

12 Oct 2020